STSA News and Press, Satsuma Pharmaceuticals Inc. From 03/07/21

Satsuma's lead and only candidate STS101 targeting treatment of acute migraines failed a pivotal trial in September last year. After a long silence, management has announced that it will launch a 2nd pivotal trial sometime in 2022, and has taken learnings from the 1st trial is confide...

Satsuma Pharmaceuticals ([[STSA]] +13.0%) agrees to sell 14,084,507 shares of its common stock to certain institutional investors in a private investment in public equity (‘PIPE’) financing.Gross proceeds from the PIPE to be ~$80M, based on the offering price of $5.68/share.Fina...

Gainers: Morphic (MORF) +104%, electroCore (ECOR) +51%, Apollo Endosurgery (APEN) +24%, ASLAN Pharmaceuticals (ASLN) +23%, Satsuma Pharmaceuticals (STSA) +19%.Losers: Athenex (ATNX) -51%, Ontrak (OTRK) -48%, CorMedix (...

Satsuma Pharmaceuticals (STSA) shares jump nearly 25% premarket after the company announced plans of initiating a phase 3 trial for its STS101 (dihydroergotamine ((DHE)) nasal powder) migraine treatment in mid-2021, with topline results expected in the second half of 2022....

ASLAN Pharmaceuticals Limited (ASLN) +71% as ASLAN004 shows positive effect in atopic dermatitis.Apollo Endosurgery (APEN) +47% after receiving a Breakthrough Device Designation from the USFDA for the Orbera® Intragastric Balloon.electroCore (ECOR) +39% on exclusive distri...

-New STS101 Phase 3 efficacy trial planned to begin mid-2021 with topline results expected second half of 2022- -Proceeds from $80 million private placement and existing cash expected to fund operations into second half of 2023- -Conference call this morning at 8:00...

SOUTH SAN FRANCISCO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that it has agreed to sell 14,084,507 shares of its common stock to certain institutional investors in a private ...

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will participate in the Evercore ISI 3rd Annual HealthCONx Conference. Please see additional detai...

Satsuma Pharmaceuticals (STSA): Q3 GAAP EPS of -$0.69 beats by $0.02.Cash, cash equivalents and marketable securities of $82.1MPress Release For further details see: Satsuma Pharmaceuticals EPS beats by $0.02

Analysis of results from EMERGE ™ Phase 3 efficacy trial of STS101 ongoing; expect to communicate next steps by early 2021 C ash , cash equivalents and marketable securities of $ 82.1 million as of September 30 , ...